Endocrine therapy for hormone treatment-naïve advanced breast cancer

Breast

Volumn 28, Issue , 2016, Pages 161-166

  Martin, Miguel ^a   Tarruella Cobo, Sara Lopez ^a   Gilarranz, Yolanda Jerez ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Advanced breast cancer; Endocrine therapy; Endocrine therapy na ve; Metastatic breast cancer

Indexed keywords

ANASTROZOLE; EXEMESTANE; FULVESTRANT; LETROZOLE; PALBOCICLIB; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BEVACIZUMAB; ESTRADIOL; NITRILE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; FEMALE; PATHOLOGY;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ESTRADIOL; FEMALE; HUMANS; NITRILES; PIPERAZINES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; TRIAZOLES;

EID: 84974822303     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2016.05.015     Document Type: Article

References (16)

1. Bonneterre J., Thürlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18:3748-3757.
2. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
3. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
4. Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
5. Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27:4530-4535.
6. Robertson J.F., Lindemann J.P., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012, 136:503-511.
7. Ellis M.J., Llombart-Cussac A., Feltl D., Dewar J.A., Jasiówka M., Hewson N., et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 2015, 33:3781-3787.
8. Bergh J., Jönsson P.E., Lidbrink E.K., Trudeau M., Eiermann W., Brattström D., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30:1919-1925.
9. Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015, 16:25-35.
10. Martin M., Loibl S., von Minckwitz G., Morales S., Martinez N., Guerrero A., et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 2015, 33:1045-1052.
11. Dickler M.N., Barry W.T., Cirrincione C.T., Ellis M.J., Moynahan M.E., Innocenti F., et al. Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance). J Clin Oncol 2015, 33. [suppl; abstract 501].
12. Mouridsen H., Gershanovich M., Sun Y., Pérez-Carrión R., Boni C., Monnier A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
13. Zeichner S.B., Herna S., Mani A., Ambros T., Montero A.J., Mahtani R.L., et al. Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. Breast Cancer Res Treat 2015, 153:617-624.
14. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367:435-444.
15. Johnston S., Pippen J., Pivot X., Lichinitser M., Sadeghi S., Dieras V., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5546.
16. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21:2101-2109.